MediciNova Meets With FDA for End-of-Phase 2 Meeting for MN-221 for the Treatment of Acute Exacerbations of Asthma

[at noodls] – MediciNova Meets With FDA for End-of-Phase 2 Meeting for MN-221 for the Treatment of Acute Exacerbations of Asthma SAN DIEGO, Oct. 22, 2012 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company … more

View todays social media effects on MNOV

View the latest stocks trending across Twitter. Click to view dashboard